ǂa ǂretrospective analysis of patients treated through an access program
Oliver Illini (Avtor), Maximilian J Hochmair (Avtor), Hannah Fabikan (Avtor), Christoph Weinlinger (Avtor), Amanda Tufman (Avtor), Aurélie Swalduz (Avtor), Kristina Lamberg (Avtor), Sayed M. S. Hashemi (Avtor), Florian Huemer (Avtor), Anders Vikström (Avtor), Katja Mohorčič (Avtor)

Povzetek

Introduction: Rearranged during transfection (RET) gene fusions are rare genetic drivers in non-small cell lung cancer (NSCLC). Selective RET-inhibitors such as selpercatinib have shown therapeutic activity in early clinical trials; however, their efficacy in the real-world setting is unknown. Methods: A retrospective efficacy and safety analysis was performed on data from RET fusion-positive NSCLC patients who participated in a selpercatinib access program (named patient protocol) between August 2019 and January 2021. Results: Data from 50 patients with RET fusion-positive advanced NSCLC treated with selpercatinib at 27 centers in 12 countries was analyzed. Most patients were Non-Asian (90%), female (60%), never-smokers (74%), with a median age of 65 years (range, 38-89). 32% of the patients had known brain metastasis at the time of selpercatinib treatment. Overall, 13 patients were treatment-naïve, while 37 were pretreated with a median of three lines of therapy (range, 1-8). The objective response rate (ORR) was 68% [95% confidence interval (CI), 53-81] in the overall population. The disease control rate was 92%. The median progression-free survival was 15.6 months (95% CI, 8.8-22.4) after a median follow-up of 9 months. In patients with measurable brain metastases (n=8) intracranial ORR reached 100%. In total, 88% of patients experienced treatment-related adverse events (TRAEs), a large majority of them being grade 1 or 2. The most common grade >/=3 TRAEs were increased liver enzyme levels (in 10% of patients), prolonged QTc time (4%), abdominal pain (4%), hypertension (4%), and fatigue/asthenia (4%). None of patients discontinued selpercatinib treatment for safety reasons. No new safety concerns were observed, nor where there any treatment-related death. Conclusions: In this real-world setting, the selective RET-inhibitor selpercatinib demonstrated durable systemic and intracranial antitumor activity in RET fusion-positive NSCLC and was well tolerated.

Ključne besede

podatki iz resničnega življenja;selperactinib;tarčna terapija;zaviralci tirozinskih kinaz;real-world data;selpercatinib;targeted therapy;tyrosine kinase inhibitor;

Podatki

Jezik: Angleški jezik
Leto izida:
Tipologija: 1.01 - Izvirni znanstveni članek
Založnik: Sage Journals
UDK: 616-006
COBISS: 66935555 Povezava se bo odprla v novem oknu
ISSN: 1758-8359
Št. ogledov: 736
Št. prenosov: 337
Ocena: 0 (0 glasov)
Metapodatki: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Ostali podatki

Sekundarne ključne besede: Carcinoma, non-small cell lung;Drug therapy;Genetics;Molecular targeted therapy;Nedrobnocelični karcinom pljuč;Terapija z zdravili;Genetika;Molekularna tarčna terapija;
Komentar vira: Nasl. z nasl. zaslona; Soavtorica iz Slovenije: Katja Mohorčič; Opis vira z dne 14. 6. 2021;
Strani: str. 1-17
Zvezek: ǂVol. ǂ13
Čas izdaje: 2021
DOI: 10.1177/17588359211019675
ID: 13032370